Thomas Knickelbine Minneapolis Heart Institute Foundation

Thomas Knickelbine, MD, FACC, FSCAI, FSCCT

Director, Lipid Research

Dr. Thomas Knickelbine is director of lipid research at Minneapolis Heart Institute®, where he has actively practiced cardiology since 1996. He is co-director of HeartScan Minnesota®, which he founded in 1999 and helped pioneer the initial calcium scoring program in the state of Minnesota. He has published multiple abstracts, presentations and papers surrounding the need for early detection and optimal treatment of coronary artery plaque. Dr. Knickelbine is board certified in cardiovascular disease and cardiovascular CT and has Level III training in cardiac and peripheral CT. His special interests include preventive cardiology and lipid management, coronary calcium scoring, echocardiography, diagnostic imaging, and coronary angiography.

Back to Prevention Team

Thomas Knickelbine Minneapolis Heart Institute Foundation
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.